SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (402)10/22/1997 10:18:00 PM
From: William Strop  Respond to of 1972
 
PB,

Thanks for the links. Always useful to read this information. I really can't answer at any intelligent level re: the GeneMedicine patents. In the past, I have always called Vical IR to get some degree of knowledge. I know from my past experiences in talking to them that there are many, many variations of these patents. I would probably have to study full time just to figure them out.

I like Vical because of the patents they hold, the partners they have and the simplicity of their technology. Hopefully patience will be rewarded.

Btw, this thread is usually quite quiet unless Vical has made at least a 2 point move (either direction).

Bill



To: Pseudo Biologist who wrote (402)10/24/1997 3:35:00 PM
From: dbuki  Read Replies (1) | Respond to of 1972
 
GeneMedicine's recent Patent No.5,676,954 seems to conflict with Vical Patent No.5,459,127 "Use of Cationic Lipids to Deliver Genes In Vivo", issued in 1995. This conflict would only involve the Leuvectin/Allovectin cancer effort where Vical is using lipid molecules (cytofectins) for delivery. It has no bearing on Vical's all important naked DNA vaccines.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News